AU2001253765A1 - Method of treating dry eye disease with nicotinic acetylcholine receptor agonists - Google Patents

Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Info

Publication number
AU2001253765A1
AU2001253765A1 AU2001253765A AU5376501A AU2001253765A1 AU 2001253765 A1 AU2001253765 A1 AU 2001253765A1 AU 2001253765 A AU2001253765 A AU 2001253765A AU 5376501 A AU5376501 A AU 5376501A AU 2001253765 A1 AU2001253765 A1 AU 2001253765A1
Authority
AU
Australia
Prior art keywords
receptor agonists
dry eye
acetylcholine receptor
eye disease
nicotinic acetylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253765A
Inventor
Mathew Cowlen
Ward M. Peterson
Benjamin R. Yerxa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AU2001253765A1 publication Critical patent/AU2001253765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001253765A 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists Abandoned AU2001253765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09557059 2000-04-21
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
AU2001253765A1 true AU2001253765A1 (en) 2001-11-07

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253765A Abandoned AU2001253765A1 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Country Status (8)

Country Link
US (1) US6277855B1 (en)
EP (1) EP1214062B1 (en)
JP (1) JP2003531168A (en)
AR (1) AR028026A1 (en)
AT (1) ATE253912T1 (en)
AU (1) AU2001253765A1 (en)
DE (1) DE60101201D1 (en)
WO (1) WO2001080844A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
EP1274444B1 (en) * 2000-03-16 2013-05-15 THE McLEAN HOSPITAL CORPORATION Cdp-choline and uridine for the treatment of alcohol abuse
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
WO2004012674A2 (en) * 2002-08-02 2004-02-12 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA05004121A (en) * 2002-10-18 2006-02-17 Molichem Medicines Inc Methods of treating dry eye disease with lantibiotics.
CN100430066C (en) * 2002-11-08 2008-11-05 麦克莱恩医院 Compounds for the treatment of tobacco dependence and withdrawal
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
WO2004058160A2 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
KR20120035220A (en) * 2003-01-22 2012-04-13 센주 세이야꾸 가부시키가이샤 Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (en) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション Methods for treating mental disorders, substance abuse disorders, and other disorders using combinations comprising omega-3 fatty acids
WO2005060984A1 (en) * 2003-12-12 2005-07-07 Yee Richard W Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
ES2342085T3 (en) * 2004-05-21 2010-07-01 Senju Pharmaceutical Co., Ltd. PERCUTANEOUS ABSORPTION OPHTHALMIC PREPARATION CONTAINING A MUSCARINIC RECEIVER AGONIST.
JP4932480B2 (en) * 2004-06-03 2012-05-16 千寿製薬株式会社 Corneal sensory recovery agent containing amide compound
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2007013661A1 (en) * 2005-07-26 2007-02-01 Senju Pharmaceutical Co., Ltd. Percutaneously absorbable ophthalmic preparation
FR2889847B1 (en) 2005-08-18 2007-10-05 Sanofi Aventis Sa DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO [3.2.1] OCTAVE, THEIR PREPARATION IN THERAPEUTICS.
CA2949643C (en) 2005-09-27 2018-05-15 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (en) * 2007-11-19 2009-05-28 Fluoron Gmbh infusion
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2009139470A1 (en) * 2008-05-16 2009-11-19 学校法人聖マリアンナ医科大学 Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CN102216289A (en) * 2008-10-14 2011-10-12 塞扣吉尼克斯公司 Nicotinic acetylcholine receptor ligands and the uses thereof
JP2012517402A (en) * 2009-02-11 2012-08-02 ヘグルンド、エー．エス． Composition for buccal absorption of nicotine for smoking cessation
TWI455722B (en) 2010-06-04 2014-10-11 Pfizer Vaccines Llc Conjugates for the prevention or treatment of nicotine addiction
AU2011328900B2 (en) 2010-11-16 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
AU2012205791B2 (en) * 2011-01-10 2016-11-03 Invion, Ltd. Use of beta-adrenergic inverse agonists for smoking cessation
ES2822301T3 (en) 2011-06-10 2021-04-30 Tissuetech Inc Fetal Support Tissue Processing Methods
CA3133869A1 (en) 2011-08-26 2013-03-07 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (en) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Method of treating blepharoconjunctival form of dry eye syndrome
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
US10155108B2 (en) 2013-04-19 2018-12-18 Oculeve, Inc. Nasal stimulation devices and methods
CN106470673B (en) 2014-02-25 2020-01-31 奥库利维公司 Polymer formulations for nasolacrimal stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
EP3171928B1 (en) 2014-07-25 2020-02-26 Oculeve, Inc. Stimulation patterns for treating dry eye
EP3209295B2 (en) * 2014-10-20 2023-12-06 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
BR112017008267A2 (en) 2014-10-22 2017-12-19 Oculeve Inc Devices and methods for treating dry eye
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
CN107073044A (en) * 2014-11-05 2017-08-18 组织技术公司 Composition and method for promoting nerve growth and regeneration
WO2016109639A2 (en) 2014-12-31 2016-07-07 Brown J David Glaucoma treatment devices and methods
CN107864623A (en) * 2015-05-21 2018-03-30 摩纳哥奥夫塔尔米斯公司 Combination as the lipoic acid and taurine of osmoprotectant
JP2017052723A (en) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ Dry eye improver
CA3000402A1 (en) * 2015-09-30 2017-04-06 Microoptx Inc. Dry eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
IL299204A (en) * 2016-04-07 2023-02-01 Oyster Point Pharma Inc Methods of treating ocular conditions
EP3442583B1 (en) 2016-04-12 2024-04-10 Arturo Solis Herrera Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
RU2019118600A (en) 2016-12-02 2021-01-11 Окулив, Инк. APPARATUS AND METHOD FOR MAKING DRY EYE SYNDROME PREDICTION AND TREATMENT RECOMMENDATIONS
TW202019424A (en) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 Methods of treating ocular conditions
WO2023279162A1 (en) * 2021-07-07 2023-01-12 University Of Canberra Methods of treatment and inhibition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
DE69332641T2 (en) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. ANABASEIN DERIVATIVES FOR TREATING DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
WO2001080844A2 (en) 2001-11-01
JP2003531168A (en) 2003-10-21
EP1214062B1 (en) 2003-11-12
EP1214062A2 (en) 2002-06-19
AR028026A1 (en) 2003-04-23
DE60101201D1 (en) 2003-12-18
ATE253912T1 (en) 2003-11-15
US6277855B1 (en) 2001-08-21
WO2001080844A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001253765A1 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
WO2000038663A3 (en) Ep4 receptor agonists for treatment of dry eye
AU2001261835A1 (en) Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
AU2500900A (en) Apparatus and methods for treating congestive heart disease
AU2001231104A1 (en) Methods for treating diabetes
AU1948901A (en) Illuminating device for treating eye disease
AU2001269799A1 (en) Methods for treating various eye disorders
IL152511A0 (en) Apparatus and methods for treating congestive heart disease
AU2001238665A1 (en) Method of identifying partial agonists of the a2a receptor
AU2002232919A1 (en) Method for treating fibrotic diseases or other indications
AU2001289684A1 (en) Glass-ceramics, process for their preparation and use
AU2001294794A1 (en) Method and apparatus for spectrophotometry of the eye
EP1167607A3 (en) Method for the wet treatment of laundry
AU2001259775A1 (en) Method for treating retinal degeneration with purinergic receptor agonists
AU5977501A (en) Method for treating retinal degeneration with purinergic receptor agonists
AU2001237939A1 (en) Methods for treating glaucoma
AU2002246490A1 (en) Method of treating parkinson's disease
AU2002241670A1 (en) Method for treating glaucoma IB
AU1271001A (en) Method for restructuring keratin fibers
AU2000254308A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
AU2002227189A1 (en) Method and device for treating gastroesophageal reflux disease
AU3290200A (en) Treatment agents for textiles, method of producing same and their use
WO2001034547A3 (en) 15-hydroxyeicosatetraenoic acid-related compounds and methods of use
AU1037901A (en) Process for the preparation of paroxetine
AU2001258827A1 (en) Method for examining WT1-related disease